Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T80896 | ||||
Target Name | Estrogen receptor beta (ESR2) | ||||
Type of Target |
Successful |
||||
Drug Potency against Target | Drug Info | IC50 = 2800 nM | [12] | ||
1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol | Drug Info | Ki = 1.3 nM | [18] | ||
1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 9 nM | [16] | ||
1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 13 nM | [16] | ||
1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL | Drug Info | IC50 = 2.52 nM | [16] | ||
1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 7 nM | [16] | ||
2,3-diphenyl-1H-indole | Drug Info | IC50 = 171 nM | [19] | ||
2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 59 nM | [11] | ||
2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol | Drug Info | IC50 = 3660 nM | [11] | ||
2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 239 nM | [11] | ||
2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol | Drug Info | IC50 = 703 nM | [11] | ||
2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 66 nM | [11] | ||
2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol | Drug Info | IC50 = 39 nM | [11] | ||
2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol | Drug Info | IC50 = 29 nM | [5] | ||
2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol | Drug Info | IC50 = 15 nM | [5] | ||
2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol | Drug Info | IC50 = 1530 nM | [11] | ||
2-(4-Hydroxy-phenyl)-1-p-tolyl-3H-inden-5-ol | Drug Info | Ki = 1.3 nM | [18] | ||
2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol | Drug Info | IC50 = 1190 nM | [17] | ||
2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol | Drug Info | IC50 = 60 nM | [17] | ||
2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol | Drug Info | IC50 = 82 nM | [11] | ||
2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol | Drug Info | IC50 = 10 nM | [10] | ||
2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol | Drug Info | IC50 = 59 nM | [11] | ||
2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol | Drug Info | IC50 = 5.6 nM | [10] | ||
2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol | Drug Info | IC50 = 235 nM | [11] | ||
2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol | Drug Info | IC50 = 1.42 nM | [11] | ||
2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol | Drug Info | IC50 = 11 nM | [11] | ||
2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol | Drug Info | IC50 = 3.5 nM | [11] | ||
2-(4-Hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 49 nM | [11] | ||
2-(4-Hydroxy-phenyl)-benzooxazol-6-ol | Drug Info | IC50 = 50 nM | [11] | ||
2-(4-Hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 171 nM | [17] | ||
2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL | Drug Info | IC50 = 6 nM | [11] | ||
2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol | Drug Info | IC50 = 1.1 nM | [5] | ||
2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol | Drug Info | IC50 = 5 nM | [11] | ||
2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol | Drug Info | IC50 = 15 nM | [11] | ||
2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol | Drug Info | IC50 = 3 nM | [11] | ||
2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol | Drug Info | IC50 = 521 nM | [11] | ||
2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol | Drug Info | IC50 = 533 nM | [11] | ||
2-Naphthalen-1-yl-benzooxazol-6-ol | Drug Info | IC50 = 1050 nM | [11] | ||
2-phenyl-1,2'-spirobi[1H-indene]-5'-ol | Drug Info | IC50 = 1070 nM | [5] | ||
3'-Methoxy-4'Hydroxyclomiphene | Drug Info | IC50 = 780 nM | [30] | ||
3,4,6-Trihydroxy-2-(4-hydroxy-phenyl)-inden-1-one | Drug Info | IC50 = 1380 nM | [14] | ||
3,6-Dihydroxy-2-(4-hydroxy-phenyl)-inden-1-one | Drug Info | IC50 = 2625 nM | [14] | ||
3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one | Drug Info | IC50 = 46 nM | [20] | ||
3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one | Drug Info | IC50 = 49 nM | [20] | ||
3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol | Drug Info | IC50 = 254 nM | [11] | ||
3-(4-Hydroxy-phenyl)-4H-chromen-7-ol | Drug Info | IC50 = 680 nM | [15] | ||
3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol | Drug Info | IC50 = 46 nM | [11] | ||
3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol | Drug Info | IC50 = 54 nM | [11] | ||
3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol | Drug Info | IC50 = 963 nM | [11] | ||
3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol | Drug Info | IC50 = 181 nM | [11] | ||
3-chloro-4-(4-hydroxyphenyl)salicylaldoxime | Drug Info | Ki = 12 nM | [26] | ||
3-hydroxy-4,10-dimethyl-6H-benzo[c]chromen-6-one | Drug Info | IC50 = 326 nM | [20] | ||
3-hydroxy-4,7-dimethyl-6H-benzo[c]chromen-6-one | Drug Info | IC50 = 93 nM | [20] | ||
3-hydroxy-4-methyl-6H-benzo[c]chromen-6-one | Drug Info | IC50 = 1450 nM | [20] | ||
3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one | Drug Info | IC50 = 90 nM | [20] | ||
4',5,7-trihydroxy-6,8-dimethylisoflavone | Drug Info | IC50 = 880 nM | [4] | ||
4,10-dimethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 74 nM | [20] | ||
4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 24 nM | [20] | ||
4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 45 nM | [20] | ||
4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 9 nM | [20] | ||
4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 8 nM | [20] | ||
4,7-dimethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 88 nM | [20] | ||
4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol | Drug Info | IC50 = 137 nM | [19] | ||
4-(2-phenyl-1H-indol-3-yl)phenol | Drug Info | IC50 = 1.12 nM | [19] | ||
4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol | Drug Info | IC50 = 11.9 nM | [19] | ||
4-(3-phenyl-1H-indol-2-yl)phenol | Drug Info | IC50 = 355 nM | [19] | ||
4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol | Drug Info | IC50 = 25 nM | [11] | ||
4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol | Drug Info | IC50 = 105 nM | [11] | ||
4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol | Drug Info | IC50 = 3 nM | [11] | ||
4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol | Drug Info | IC50 = 718 nM | [11] | ||
4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 4.3 nM | [17] | ||
4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 4.6 nM | [17] | ||
4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 52 nM | [17] | ||
4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 75 nM | [17] | ||
4-Naphthalen-2-yl-phenol | Drug Info | IC50 = 245 nM | [16] | ||
4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol | Drug Info | IC50 = 10 nM | [6] | ||
4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol | Drug Info | IC50 = 240 nM | [6] | ||
4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol | Drug Info | IC50 = 70 nM | [6] | ||
4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol | Drug Info | IC50 = 200 nM | [6] | ||
4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol | Drug Info | IC50 = 15 nM | [6] | ||
5,7-dihydroxy-3-phenyl-3H-quinazolin-4-one | Drug Info | IC50 = 18472 nM | [21] | ||
5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 88 nM | [17] | ||
5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol | Drug Info | IC50 = 157 nM | [11] | ||
5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol | Drug Info | IC50 = 30 nM | [17] | ||
6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 2.8 nM | [16] | ||
6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 2.3 nM | [16] | ||
6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 1.4 nM | [16] | ||
6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 2 nM | [16] | ||
6-(2-Hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 2000 nM | [16] | ||
6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 8.4 nM | [16] | ||
6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 11 nM | [16] | ||
6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 5 nM | [16] | ||
6-(3-Hydroxy-phenyl)-naphthalen-1-ol | Drug Info | IC50 = 205 nM | [16] | ||
6-(3-Hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 30 nM | [16] | ||
6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 27 nM | [16] | ||
6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 10 nM | [16] | ||
6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol | Drug Info | IC50 = 114 nM | [16] | ||
6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol | Drug Info | IC50 = 17 nM | [16] | ||
6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol | Drug Info | IC50 = 199 nM | [16] | ||
6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol | Drug Info | IC50 = 748 nM | [16] | ||
6-(4-Hydroxy-phenyl)-naphthalen-1-ol | Drug Info | IC50 = 5.8 nM | [16] | ||
6-(4-Hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 16 nM | [17] | ||
6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 16 nM | [11] | ||
6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol | Drug Info | IC50 = 3.2 nM | [20] | ||
6-Phenyl-naphthalen-2-ol | Drug Info | IC50 = 374 nM | [16] | ||
7-(3-Hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 566 nM | [16] | ||
7-(4-Hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 44 nM | [16] | ||
7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 13 nM | [11] | ||
7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol | Drug Info | IC50 = 2 nM | [10] | ||
7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 79 nM | [11] | ||
7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol | Drug Info | IC50 = 1.6 nM | [10] | ||
7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 13 nM | [11] | ||
7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol | Drug Info | IC50 = 15 nM | [11] | ||
7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one | Drug Info | IC50 = 1530 nM | [22] | ||
7-hydroxy-3-(4-hydroxyphenyl)-3H-quinazolin-4-one | Drug Info | IC50 = 8609 nM | [21] | ||
7-Phenyl-naphthalen-2-ol | Drug Info | IC50 = 527 nM | [16] | ||
8-(2,2-dimethylpropyl)naringenin | Drug Info | IC50 = 141 nM | [23] | ||
8-(2-methylpropyl)naringenin | Drug Info | IC50 = 37 nM | [23] | ||
8-(3-methylbutyl)naringenin | Drug Info | IC50 = 59 nM | [23] | ||
8-benzylnaringenin | Drug Info | IC50 = 244 nM | [23] | ||
8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 2.3 nM | [16] | ||
8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol | Drug Info | IC50 = 1.6 nM | [16] | ||
8-methylnaringenin | Drug Info | IC50 = 863 nM | [23] | ||
8-n-heptylnaringenin | Drug Info | IC50 = 69 nM | [23] | ||
8-n-nonylnaringenin | Drug Info | IC50 = 113 nM | [23] | ||
8-n-pentylnaringenin | Drug Info | IC50 = 97 nM | [23] | ||
8-n-propylnaringenin | Drug Info | IC50 = 29 nM | [23] | ||
8-n-undecylnaringenin | Drug Info | IC50 = 421 nM | [23] | ||
Afimoxifene | Drug Info | IC50 = 20 nM | [27] | ||
ARZOXIFENE | Drug Info | IC50 = 66.3 nM | [24] | ||
BITHIONOL | Drug Info | IC50 = 8147.15 nM | [29] | ||
BROUSSONIN A | Drug Info | IC50 = 1800 nM | [28] | ||
COUMESTROL | Drug Info | IC50 = 18.6 nM | [15] | ||
daidzein | Drug Info | IC50 = 1200 nM | [4] | ||
DIHYDRORALOXIFENE | Drug Info | IC50 = 0.52 nM | [1] | ||
Doxorubicin-Formaldehyde Conjugate | Drug Info | IC50 = 300 nM | [8] | ||
EFFUSOL | Drug Info | IC50 = 12 nM | [20] | ||
ERA-923 | Drug Info | IC50 = 40 nM | [3] | ||
Geldanamycin-estradiol hybrid | Drug Info | IC50 = 80 nM | [2] | ||
GNF-PF-3037 | Drug Info | IC50 = 2611.21 nM | [29] | ||
HE2100 | Drug Info | IC50 = 9.9 nM | [25] | ||
HEXESTROL | Drug Info | IC50 = 2 nM | |||
MORIN | Drug Info | IC50 = 2927.18 nM | [29] | ||
Nafoxidine | Drug Info | IC50 = 40.9 nM | [32] | ||
NARINGENIN | Drug Info | IC50 = 13473 nM | [23] | ||
ONAPRISTONE | Drug Info | Ki < 20 nM | [31] | ||
SOPHORAFLAVANONE B | Drug Info | IC50 = 68 nM | [23] | ||
THIOGENISTEIN | Drug Info | IC50 = 1340 nM | [21] | ||
TUPICHINOL C | Drug Info | IC50 = 14700 nM | [28] | ||
WAY-169916 | Drug Info | IC50 = 106 nM | [13] | ||
WAY200070 | Drug Info | IC50 = 2 nM | [11] | ||
ZK-164015 | Drug Info | IC50 = 1.4 nM | [9] | ||
[1,1':2',1'']Terphenyl-4'-carbaldehyde oxime | Drug Info | Ki = 0.27 nM | [7] | ||
References | |||||
REF 1 | Synthesis and biological activity of trans-2,3-dihydroraloxifene. Bioorg Med Chem Lett. 1999 Apr 19;9(8):1137-40. | ||||
REF 2 | Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8. | ||||
REF 3 | Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem. 2001 May 24;44(11):1654-7. | ||||
REF 4 | Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis. J Nat Prod. 2002 Dec;65(12):1749-53. | ||||
REF 5 | 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83. | ||||
REF 6 | Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91. | ||||
REF 7 | Novel estrogen receptor ligands based on an anthranylaldoxime structure: role of the phenol-type pseudocycle in the binding process. J Med Chem. 2003 Sep 11;46(19):4032-42. | ||||
REF 8 | Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells. J Med Chem. 2004 Feb 26;47(5):1193-206. | ||||
REF 9 | Synthesis and biological evaluation of stilbene-based pure estrogen antagonists. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4659-63. | ||||
REF 10 | 7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9. | ||||
REF 11 | Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. | ||||
REF 12 | Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers-molecular modeling studies. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5919-24. | ||||
REF 13 | Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8. | ||||
REF 14 | Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3137-42. | ||||
REF 15 | Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative ... J Med Chem. 2005 May 19;48(10):3463-6. | ||||
REF 16 | ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. | ||||
REF 17 | ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. | ||||
REF 18 | Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands. J Med Chem. 2005 Sep 22;48(19):5989-6003. | ||||
REF 19 | Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. | ||||
REF 20 | 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. | ||||
REF 21 | Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. J Med Chem. 2006 Apr 20;49(8):2440-55. | ||||
REF 22 | The discovery of tetrahydrofluorenones as a new class of estrogen receptor beta-subtype selective ligands. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3489-94. | ||||
REF 23 | Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. | ||||
REF 24 | Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92. | ||||
REF 25 | Androstene-3,5-dienes as ER-beta selective SERMs. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6295-8. | ||||
REF 26 | Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta. J Med Chem. 2008 Mar 13;51(5):1344-51. | ||||
REF 27 | Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators. Bioorg Med Chem. 2008 Nov 1;16(21):9554-73. | ||||
REF 28 | New estrogenic compounds isolated from Broussonetia kazinoki. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3764-7. | ||||
REF 29 | In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. | ||||
REF 30 | Phenolic metabolites of clomiphene: [(E,Z)-2-[4-(1,2-diphenyl-2-chlorovinyl)phenoxy]ethyl]diethylamine. Preparation, electrophilicity, and effects ... J Med Chem. 1989 Jan;32(1):192-7. | ||||
REF 31 | Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether. J Med Chem. 1996 Apr 26;39(9):1778-89. | ||||
REF 32 | Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthal... J Med Chem. 1998 Jul 30;41(16):2928-31. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.